Renal Cell Carcinoma Reagents

Home > Featured Products > Oncology Research > Renal Cell Carcinoma

Renal Cell Carcinoma Reagents — VEGFR, PD-L1, CA9, CD70, HIF | abinScience

RCC, particularly clear cell (ccRCC), is driven by VHL loss and HIF pathway activation leading to VEGF overexpression. First-line therapy combines VEGFR TKIs with immune checkpoint inhibitors. abinScience provides reagents for VEGF/VEGFR, PD-1/PD-L1/CTLA-4, HIF/VHL, CA9/CAIX, CD70, and next-generation checkpoints (LAG-3, TIGIT, TIM-3). RUO

Key Biomarkers & Targets

VEGF / VEGFR

Angiogenesis Axis

Central pathway in ccRCC; sunitinib, pazopanib, cabozantinib, and bevacizumab all target the VEGF axis. 260+ combined products.

Antibodies • Proteins • Biosimilars

PD-1 / PD-L1 / CTLA-4

Checkpoint Combinations

Nivolumab + ipilimumab and pembrolizumab + axitinib define first-line ccRCC treatment. 400+ combined reagents.

Antibodies • Proteins • Biosimilars

HIF / VHL

Hypoxia Pathway

VHL loss drives HIF-2α stabilization in ccRCC; belzutifan (HIF-2α inhibitor) is first-in-class. 40 combined antibodies and proteins.

Antibodies • Proteins

CA9 / CAIX

Carbonic Anhydrase IX

HIF target gene product; ccRCC biomarker and emerging ADC target. Antibodies with FCM and ELISA validation. 40+ products.

Antibodies • Proteins

CD70

TNFSF7

Overexpressed in ccRCC; ADC target (cusatuzumab-based approaches). 32 antibodies and biosimilar proteins.

Antibodies • Biosimilars

LAG-3 / TIGIT / TIM-3

Next-Gen Checkpoints

Under active investigation as combination partners with PD-1 blockade in RCC. 125+ combined products.

Antibodies • Proteins • Biosimilars

Why Researchers Choose abinScience for RCC

VHL-HIF-VEGF Pathway DepthVHL, HIF-1α/2α, VEGF-A, VEGFR1/2, and CA9 antibodies covering the entire ccRCC driver axis from genetic loss to effector targets.

Multi-Checkpoint PortfolioPD-1, PD-L1, CTLA-4, LAG-3, TIGIT, TIM-3 for studying combination immunotherapy strategies and resistance in RCC.

Emerging ADC TargetsCD70, CA9/CAIX, and TROP2 antibodies and recombinant proteins for kidney cancer-specific ADC and radioimmunotherapy development.

Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

VHL-HIF pathway characterization: Profile VHL loss, HIF-2α stabilization, and downstream CA9/VEGF expression in ccRCC cell lines and patient tissue to study belzutifan mechanism of action.
Anti-angiogenic drug resistance: Use VEGFR, MET, AXL, and FGFR antibodies to characterize compensatory RTK signaling as resistance mechanisms to sunitinib and cabozantinib.
IO combination biomarkers: Profile PD-L1 + LAG-3 + TIGIT co-expression on tumor and immune cells to identify rational dual-checkpoint blockade combinations in RCC.
ccRCC diagnostic confirmation: CA9, PAX8, and CD10 antibodies available for RCC research. See product pages for validated applications.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Do you carry CA9/CAIX antibodies for RCC IHC?

Anti-CA9 monoclonal antibodies with FC and ELISA validation (e.g., clones SAA0152, SAA0475). Research-grade girentuximab biosimilar with ELISA and FACS validation also available.

Which VHL/HIF pathway antibodies do you offer?

Anti-VHL and HIF pathway antibodies, plus recombinant HIF proteins available. See product pages for validated applications.

Do you have CD70 reagents for ADC development?

Anti-CD70 antibodies and research-grade biosimilar proteins available. See product pages for validated applications.

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.